RIVAROXABAN Drug Interactions
Also known as: rivaroxaban
RIVAROXABAN (brand name: rivaroxaban) is a Anticoagulants. 1 INDICATIONS & USAGE Rivaroxaban is a factor Xa inhibitor indicated: to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients…RIVAROXABAN has 10 documented drug interactions in our database, including 0 contraindicated, 10 major, 0 moderate, and 0 minor interactions.
0
Contraindicated
10
Major
0
Moderate
0
Minor
Combining naproxen with rivaroxaban significantly increases your risk of bleeding, especially from the stomach or intestines. This combination should generally be avoided due to the serious potential for harm.
Mechanism
Naproxen, a non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and impairing platelet aggregation, while also causing direct gastric irritation. Rivaroxaban is a direct oral anticoagulant (DOAC) that selectively inhibits Factor Xa, preventing thrombin generation and clot formation. The concomitant use of these agents results in additive antiplatelet and anticoagulant effects, leading to a synergistic increase in bleeding risk.
Clinical Management
The primary clinical effect is a substantially increased risk of serious bleeding events, including gastrointestinal bleeding (e.g., ulcers, hemorrhage), intracranial hemorrhage, and other major bleeding. Studies indicate that concomitant use of NSAIDs with DOACs can increase the risk of major bleeding by 2 to 4-fold compared to DOACs alone, with GI bleeding being particularly prominent. This combination should generally be avoided. If an NSAID is absolutely necessary, consider alternative pain management strategies or a lower-risk analgesic. If no alternative is feasible, use the lowest effective dose of naproxen for the shortest possible duration, and monitor closely for signs of bleeding (e.g., black/tarry stools, unusual bruising, blood in urine). Proton pump inhibitors (PPIs) may be considered for gastroprotection, but do not eliminate the risk. Consult a physician for alternative pain relief or anticoagulant strategies.
Combining Etodolac, an NSAID, with Rivaroxaban, an anticoagulant, significantly increases your risk of serious bleeding, especially in the stomach or intestines. Your doctor will likely recommend avoiding this combination.
Mechanism
Etodolac inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis and impairing platelet aggregation. Rivaroxaban directly inhibits Factor Xa, preventing thrombin generation and clot formation. The concurrent use of these agents results in an additive antiplatelet and anticoagulant effect, profoundly increasing the risk of hemorrhage.
Clinical Management
This combination significantly elevates the risk of major bleeding events, including gastrointestinal bleeding, intracranial hemorrhage, and other site-specific bleeding. Studies show that combining NSAIDs with DOACs can increase the risk of GI bleeding by 2-3 fold compared to DOACs alone, with an absolute risk of serious bleeding potentially exceeding 2-5% annually. This combination should generally be avoided due to the high risk of serious bleeding. If an NSAID is absolutely necessary, consider alternative pain management strategies or a short course of a COX-2 selective NSAID (like celecoxib) with extreme caution, and closely monitor for signs of bleeding. Proton pump inhibitor co-therapy should be considered if an NSAID is unavoidable. Regular clinical assessment and patient education on bleeding symptoms are crucial.
Combining aspirin with rivaroxaban significantly increases your risk of serious bleeding, including bleeding in the stomach or brain. This combination should generally be avoided unless specifically directed and closely monitored by your doctor.
Mechanism
Aspirin is an antiplatelet agent that irreversibly inhibits cyclooxygenase (COX-1), reducing thromboxane A2 production and impairing platelet aggregation. Rivaroxaban is a direct oral anticoagulant (DOAC) that directly inhibits Factor Xa, preventing thrombin generation and clot formation. The concurrent use of these agents leads to a synergistic inhibition of both primary hemostasis (platelet function) and secondary hemostasis (coagulation cascade), resulting in a substantially elevated risk of hemorrhage.
Clinical Management
The primary clinical effect is a significantly increased risk of bleeding, which can range from minor events like bruising and nosebleeds to severe, life-threatening hemorrhages such as gastrointestinal bleeding, intracranial hemorrhage, or retroperitoneal bleeding. Studies have shown that combining NSAIDs with DOACs can increase the risk of major bleeding by 2 to 3 times compared to DOAC monotherapy. This combination should generally be avoided due to the high bleeding risk. If concurrent use is deemed absolutely necessary (e.g., for specific cardiovascular indications), it must be done under strict medical supervision with careful monitoring for signs of bleeding. Consider alternative pain management options if aspirin is for analgesia. If aspirin is for antiplatelet therapy, reassess the absolute need and duration, and consider lowest effective doses. Patient education on bleeding symptoms is crucial.
Combining ibuprofen with rivaroxaban significantly increases your risk of serious bleeding, including bleeding in the stomach or intestines. This combination should generally be avoided.
Mechanism
Ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes, leading to decreased prostaglandin synthesis and impaired platelet aggregation. Rivaroxaban is a direct oral anticoagulant (DOAC) that directly inhibits Factor Xa, preventing thrombin generation and clot formation. The concurrent use of these agents results in additive antiplatelet and anticoagulant effects, markedly increasing the risk of bleeding.
Clinical Management
The primary clinical effect is a substantially elevated risk of bleeding. This can manifest as gastrointestinal bleeding (e.g., stomach ulcers, melena, hematemesis), bruising, nosebleeds, or more severe internal bleeding. Studies show that combining NSAIDs with DOACs can increase the risk of major bleeding by 2 to 3 times compared to DOAC monotherapy. This combination should be avoided if possible. If pain relief is necessary, consider alternative analgesics such as acetaminophen. If an NSAID is absolutely required, use the lowest effective dose for the shortest duration, and monitor closely for signs of bleeding. Proton pump inhibitors (PPIs) may be considered for gastroprotection, but do not eliminate the risk. Evaluate the patient's overall bleeding risk factors.
Combining indomethacin with rivaroxaban significantly increases your risk of bleeding, especially in the stomach and intestines. This combination should generally be avoided.
Mechanism
Indomethacin, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase enzymes, leading to reduced prostaglandin synthesis. This results in impaired platelet aggregation and can cause direct irritation and damage to the gastrointestinal mucosa. Rivaroxaban is a direct oral anticoagulant (DOAC) that directly inhibits Factor Xa, preventing thrombin generation and clot formation. The concurrent use of these agents leads to an additive antiplatelet and anticoagulant effect, significantly increasing the risk of bleeding.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding (e.g., ulcers, hemorrhage), but also epistaxis, hematuria, and bruising. Studies show that combining NSAIDs with DOACs can increase the risk of major bleeding by 2-3 fold compared to DOAC monotherapy. Gastrointestinal bleeding can be severe and life-threatening. This combination should generally be avoided due to the high bleeding risk. If an NSAID is absolutely necessary, consider alternative pain management strategies or a short course of a COX-2 selective NSAID (though still with caution). Close monitoring for signs of bleeding (e.g., black/tarry stools, unusual bruising, blood in urine) is essential if co-administration cannot be avoided. Proton pump inhibitors (PPIs) may be considered for gastroprotection.
Combining celecoxib (a pain reliever) with rivaroxaban (a blood thinner) significantly increases your risk of serious bleeding, including stomach bleeding. Your doctor may need to adjust your medications or monitor you closely.
Mechanism
Celecoxib, an NSAID, inhibits prostaglandin synthesis, which can impair gastric mucosal defense and inhibit platelet aggregation. Rivaroxaban is a direct oral anticoagulant that inhibits Factor Xa, preventing clot formation. The combination leads to additive antiplatelet and anticoagulant effects, alongside increased gastrointestinal mucosal damage, substantially elevating bleeding risk.
Clinical Management
The primary clinical effect is a significantly increased risk of bleeding, particularly gastrointestinal bleeding, but also other sites like intracranial hemorrhage. Studies show that combining NSAIDs with DOACs can increase the risk of major bleeding by 1.5 to 2-fold compared to DOACs alone, with gastrointestinal bleeding being the most common and serious manifestation. Avoid concomitant use if possible. If concurrent use is unavoidable, use the lowest effective dose of celecoxib for the shortest duration. Closely monitor for signs and symptoms of bleeding (e.g., black stools, unusual bruising, blood in urine). Consider gastroprotective agents (e.g., PPIs) if NSAID use is essential. Evaluate alternative pain management strategies that do not increase bleeding risk.
Combining piroxicam with rivaroxaban significantly increases your risk of bleeding, including serious internal bleeding. You should avoid taking these medications together unless specifically directed by your doctor.
Mechanism
Piroxicam, an NSAID, inhibits prostaglandin synthesis, which reduces platelet aggregation and impairs the gastroprotective lining of the stomach. Rivaroxaban is a direct oral anticoagulant that inhibits Factor Xa, preventing clot formation. The concurrent use of these drugs leads to an additive antiplatelet and anticoagulant effect, and increased gastrointestinal mucosal damage, synergistically elevating bleeding risk.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, which can range from minor bruising or nosebleeds to severe and life-threatening gastrointestinal hemorrhage, intracranial bleeding, or other internal bleeding. The risk of major bleeding can be several-fold higher compared to rivaroxaban alone. This combination should generally be avoided. If an NSAID is absolutely necessary, consider alternative pain management strategies or a different NSAID with a lower GI bleeding risk (e.g., COX-2 selective, if appropriate) for the shortest duration possible, with close monitoring for bleeding. Proton pump inhibitors (PPIs) should be co-prescribed to reduce GI bleeding risk. Patients must be educated on bleeding signs and symptoms.
Combining meloxicam with rivaroxaban significantly increases your risk of bleeding, including serious internal bleeding. This combination should generally be avoided.
Mechanism
Meloxicam, an NSAID, inhibits cyclooxygenase enzymes, which reduces prostaglandin synthesis. This leads to impaired platelet aggregation and can cause direct gastric mucosal irritation. Rivaroxaban is a direct factor Xa inhibitor, which prevents clot formation. The combination results in additive antiplatelet and anticoagulant effects, significantly increasing bleeding risk.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding. This can manifest as gastrointestinal bleeding (e.g., stomach ulcers, melena, hematemesis), intracranial hemorrhage, hematuria, or excessive bleeding from minor injuries. The risk of serious gastrointestinal bleeding can be several-fold higher compared to either drug alone. This combination should generally be avoided due to the high bleeding risk. If an NSAID is absolutely necessary, consider alternative pain management strategies or a short course of a COX-2 selective NSAID (like celecoxib) with extreme caution, proton pump inhibitor co-therapy, and close monitoring for bleeding. Patients should be educated on bleeding signs and symptoms and seek immediate medical attention if they occur. If possible, consider alternative analgesics like acetaminophen.
Combining diclofenac with rivaroxaban significantly increases your risk of bleeding, especially from the stomach or intestines. This combination should generally be avoided due to the serious bleeding potential.
Mechanism
Diclofenac, a non-steroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis, which can impair gastric mucosal protection and inhibit platelet aggregation. Rivaroxaban is a direct oral anticoagulant that inhibits Factor Xa, preventing thrombin generation and clot formation. The concurrent use of these agents results in additive antiplatelet and anticoagulant effects, leading to a heightened risk of hemorrhage.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, which can manifest as gastrointestinal bleeding (e.g., melena, hematemesis), epistaxis, hematuria, bruising, or more severe internal hemorrhages. Studies suggest that the risk of major bleeding can be several-fold higher when NSAIDs are combined with DOACs compared to DOACs alone. This combination should be avoided if possible. If concomitant use is unavoidable, the patient must be closely monitored for signs and symptoms of bleeding, and the lowest effective dose of diclofenac for the shortest duration should be used. Consider alternative pain management strategies that do not increase bleeding risk, such as acetaminophen. Proton pump inhibitor prophylaxis may be considered if NSAID use is essential, but it does not eliminate the systemic bleeding risk.
Combining ketorolac with rivaroxaban significantly increases your risk of bleeding, including serious internal bleeding. This combination should generally be avoided.
Mechanism
Ketorolac, a non-steroidal anti-inflammatory drug (NSAID), inhibits platelet aggregation and can cause gastrointestinal irritation and ulceration. Rivaroxaban is a direct oral anticoagulant (DOAC) that inhibits Factor Xa, preventing clot formation. The concurrent use of these agents results in additive antiplatelet and anticoagulant effects, impairing hemostasis.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding, but also bleeding from other sites. This can manifest as blood in stools, dark tarry stools, vomiting blood, nosebleeds, or bruising. The risk of major bleeding can be several-fold higher compared to using either drug alone. This combination should generally be avoided due to the high risk of bleeding. If an NSAID is absolutely necessary, consider alternative pain management strategies or a short course of a COX-2 selective NSAID (e.g., celecoxib) with extreme caution and close monitoring, though even this carries significant risk. Patients must be educated on signs of bleeding and seek immediate medical attention if they occur.
For complete prescribing information:
View full RIVAROXABAN monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.